Neurodegenerative disorders, such as Alzheimer’s disease (AD), are defined as clinico-pathological entities in which a definitive diagnosis has traditionally been based on pathological hallmarks only available at autopsy. The development of biomarkers with high sensitivity and specificity has opened up the possibility of a definitive diagnosis in the clinical setting. Is a classification of neurodegenerative disorders based exclusively on biomarkers possible?
Professor Perminder Sachdev AM MBBS MD FRANZCP PhD FAHMS is Scientia Professor of Neuropsychiatry, Co-Director of the Centre for Healthy Brain Ageing (CHeBA), UNSW, and Clinical Director of the Neuropsychiatric Institute (NPI) at the Prince of Wales Hospital. He is co-chair of the Australian Dementia Network (ADNeT) and Director of the Centre of Research Excellence in Vascular Contributions to Dementia. His major areas of research are drug-induced movement disorders, brain imaging, cognitive ageing and dementia.
